Endoscopic, histologic improvements in EoE sustained at 52 weeks with etrasimod

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data.
“Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active

Related Keywords

Washington ,United States ,Bykate Burba ,Evans Dellon ,Heather Biele ,University Of North Carolina School Medicine ,Esophageal Diseases ,North Carolina School ,Digestive Disease ,Digestive Disease Week ,Eoe Histology Scoring System ,Eoe Endoscopic Reference Score ,Patient Global Impression ,Dysphagia Symptom Questionnaire ,